Clinical Trial Update: Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of rituximab plus pembrolizumab in relapsed/refractory Waldenstrom macroglobulinemia has completed, with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenstrom Macroglobulinemia

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Rituximab (rituximab)

Snippet

Sponsor: University College, London | Conditions: Waldenstrom Macroglobulinemia | Phase 2 | Status: COMPLETED | Results posted: 2024-11-07